{"id":615561,"date":"2022-09-09T19:02:01","date_gmt":"2022-09-09T19:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=615561"},"modified":"2022-09-09T19:02:01","modified_gmt":"2022-09-09T19:02:01","slug":"lyme-disease-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lyme-disease-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight_615561.html","title":{"rendered":"Lyme Disease Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight"},"content":{"rendered":"
\n
\"Lyme<\/a><\/div>\n
\n
Lyme Disease Pipeline<\/div>\n<\/div>\n<\/div>\n
Lyme Disease pipeline constitutes 7+ key companies continuously working towards developing 7+ Lyme Disease treatment therapies, analyzes DelveInsight<\/div>\n

Lyme disease or Lyme borreliosis is the most commonly transmitted tick-borne infection in the United States and among the most frequently diagnosed tick-borne infections worldwide. Lyme disease is divided into three stages: early localized, early disseminated, and late. The early localized disease is distinguished by the red ring-like expanding rash of Erythema migrans at the site of a recent tick bite.<\/p>\n

 <\/p>\n

“Lyme Disease Pipeline Insight, 2022<\/strong>” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lyme Disease Market. <\/p>\n

The Lyme Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

To know more about the Lyme Disease pipeline report, click here: Lyme Disease Pipeline Insight<\/a><\/strong><\/p>\n

 <\/p>\n

DelveInsight’s Lyme Disease Report covers around 7+ products under different phases of clinical development like<\/strong><\/p>\n

• Late-stage Lyme Disease products (Phase III)<\/p>\n

• Mid-stage Lyme Disease products (Phase II)<\/p>\n

• Early-stage Lyme Disease product (Phase I)<\/p>\n

• Pre-clinical and Discovery stage candidates<\/p>\n

• Discontinued & Inactive candidates<\/p>\n

• Lyme Disease Route of Administration<\/p>\n

 <\/p>\n

Emerging Lyme Disease Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n

• VLA 15: Valneva<\/p>\n

• CT38: Cortene<\/p>\n

And Many Others.<\/p>\n

 <\/p>\n

Further Lyme Disease product details are provided in the report. Download the Lyme Disease pipeline report to learn more about the emerging Lyme Disease therapies at:  Lyme Disease Clinical trials advancements<\/a> <\/strong><\/p>\n

 <\/p>\n

Lyme Disease Pipeline Analysis<\/strong><\/p>\n

The Lyme Disease report provides insights into: <\/strong><\/p>\n